Nosopharm Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Liquidation

Nosopharm General Information

Description

Developer of anti-infective drugs designed to treat hospital-acquired infections. The company's drugs offer odilorhabdins which is a novel class of antibiotics that targets the multidrug-resistant based on the exploitation of microbial biodiversity for pharmacological applications, enabling patients to reduce the risk of infections.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 21 avenue Georges Pompidou
  • Danica B
  • 69486 Lyon
  • France
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 21 avenue Georges Pompidou
  • Danica B
  • 69486 Lyon
  • France

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nosopharm Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Bankruptcy: Liquidation 22-Jun-2024 Completed Bankruptcy: Liquidation
6. Accelerator/Incubator Completed Pre-Clinical Trials
5. Accelerator/Incubator 28-Mar-2023 Completed Startup
4. Later Stage VC 17-Jul-2020 Completed Pre-Clinical Trials
3. Debt - General 12-Feb-2018 Completed Pre-Clinical Trials
2. Later Stage VC 28-Mar-2017 $2.53M $2.53M Completed Pre-Clinical Trials
1. Grant 07-Nov-2013 $2.59M Completed Startup
To view Nosopharm’s complete valuation and funding history, request access »

Nosopharm Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
ABSA B-2020
Class A Prefered Shares
Class A Prefered Shares 336,349 $1.126858 $7.47 $7.47 1x $7.47 26.14%
To view Nosopharm’s complete cap table history, request access »

Nosopharm Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of anti-infective drugs designed to treat hospital-acquired infections. The company's drugs offer odilorhabdin
Drug Discovery
Lyon, France
7 As of 2023

Aberdeen, United Kingdom
 

Broomfield, CO
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nosopharm Competitors (44)

One of Nosopharm’s 44 competitors is NovaBiotics, a Venture Capital-Backed company based in Aberdeen, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NovaBiotics Venture Capital-Backed Aberdeen, United Kingdom
Cerecin Venture Capital-Backed Broomfield, CO
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Eternygen Venture Capital-Backed Berlin, Germany
Alopexx Corporation Cambridge, MA
You’re viewing 5 of 44 competitors. Get the full list »

Nosopharm Patents

Nosopharm Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024200838-A1 New odilorhabdins analogues as antibiotics against multi-resistant bacteria Inactive 31-Mar-2023
WO-2021148594-A1 Chemical synthesis of the peptidic part of bioactive natural products Inactive 23-Jan-2020
AU-2015323713-A1 Novel peptide derivatives and uses thereof Active 26-Sep-2014
AU-2015323713-B2 Novel peptide derivatives and uses thereof Inactive 26-Sep-2014
EP-3197908-A1 Novel peptide derivatives and uses thereof Pending 26-Sep-2014 C07K7/06
To view Nosopharm’s complete patent history, request access »

Nosopharm Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nosopharm FAQs

  • When was Nosopharm founded?

    Nosopharm was founded in 2009.

  • Where is Nosopharm headquartered?

    Nosopharm is headquartered in Lyon, France.

  • What is the size of Nosopharm?

    Nosopharm has 7 total employees.

  • What industry is Nosopharm in?

    Nosopharm’s primary industry is Drug Discovery.

  • Is Nosopharm a private or public company?

    Nosopharm is a Private company.

  • What is Nosopharm’s current revenue?

    The current revenue for Nosopharm is .

  • How much funding has Nosopharm raised over time?

    Nosopharm has raised $5.6M.

  • Who are Nosopharm’s competitors?

    NovaBiotics, Cerecin, Inovio Pharmaceuticals, Eternygen, and Alopexx are some of the 44 competitors of Nosopharm.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process